Regentis Biomaterials (RGNT) CFO discloses multi-year stock option grant
Rhea-AI Filing Summary
REGENTIS BIOMATERIALS LTD. Chief Financial Officer Gon Ori reported an initial holding of employee stock options. These options allow the purchase of 84,951 shares of common stock at an exercise price of $4.0000 per share and expire on February 23, 2037.
The option was granted on February 23, 2026 and vests over three years, with one-sixth vesting six months after the grant date and the remainder vesting quarterly, subject to continuous employment through each vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Gon Ori
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 84,951 shares (Direct)
Footnotes (1)
- F1. This option was granted on February 23, 2026. The options shall vest on a quarterly basis, with one-sixth (1/6) of the options vesting upon the six-month anniversary of the grant date and one-twelfth (1/12) vesting on the last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did RGNT CFO Gon Ori report in this Form 3 filing?
Gon Ori reported an initial holding of employee stock options. These options relate to 84,951 shares of Regentis Biomaterials common stock, providing the right to buy shares at a fixed exercise price, subject to vesting and expiration terms described in the grant.
What is the exercise price of the RGNT CFO’s stock options?
The options have an exercise price of $4.0000 per share. This is the fixed price at which Gon Ori may purchase Regentis Biomaterials common stock upon exercise of vested options, regardless of the market price at the time of exercise.
When do the Regentis Biomaterials (RGNT) CFO stock options expire?
The options expire on February 23, 2037. After this expiration date, any unexercised portion of the grant can no longer be exercised, even if the options were fully vested prior to that time under the award’s vesting schedule.
How do the RGNT CFO’s stock options vest over time?
One-sixth of the options vest on the six-month anniversary of the February 23, 2026 grant date. Thereafter, one-twelfth vests on the last day of each three-month period, contingent on continuous employment, until full vesting on the third anniversary.
Is the RGNT CFO’s option vesting dependent on continued employment?
Yes. Vesting is conditioned on the reporting person’s continuous employment through each vesting date. If employment ends before a given vesting date, the unvested portion tied to that date and subsequent dates generally would not become exercisable under the grant terms.